Print Page  Close Window
Investor Relations
Corporate Profile

Akorn, Inc. is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is an industry leader in the development, manufacturing and marketing of generic pharmaceutical products in alternate dosage forms. The Company focuses on difficult-to-manufacture sterile and non-sterile dosage forms including, but not limited to, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays.

In order to successfully execute its strategy, Akorn continues to capitalize on its core strengths:

Research and development expertise in alternate dosage forms. The R&D efforts are primarily focused on the development of multisource generic products that are in dosage forms other than oral solid...  More >>

Stock Quote
AKRX (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$14.07
Change (%) Stock is Up 0.07 (0.50%)
Volume1,212,114
Data as of 05/25/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Notice of Waiver to Holders - 3.50% Convertible Senior Notes due June 1, 2016
Notice of Settlement Method Election - 3.50% Convertible Senior Notes Due 2016
Recent NewsMore >>
DateTitle 
04/23/18Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement
LAKE FOREST, Ill.--(BUSINESS WIRE)--Apr. 23, 2018-- Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement: “Fresenius’ attempt to terminate the transaction on the pretext that the findings from the ongoing investigation are a breach of the merger agreement is completely witho... 
Printer Friendly Version
04/22/18Akorn Issues Statement
LAKE FOREST, Ill.--(BUSINESS WIRE)--Apr. 22, 2018-- Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to Fresenius Kabi’s announcement that it is seeking to terminate the definitive merger agreement announced on April 24, 2017. “We categorically disagree with Fresenius’ accusations. The previously disclosed ongoing investigation, which is not a condition to closing, has not found any facts that would result in a material adverse eff... 
Printer Friendly Version
02/26/18Akorn Issues Statement on Investigation
LAKE FOREST, Ill., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the assistance of outside consultants, are investigating alleged breaches of FDA data integrity requirements relating to product development at the Company.  To date, the Company’s investigation has not found any facts that would result in a material impact on Akorn’s operations and the Co... 
Printer Friendly Version
Latest Investor PresentationMore >>
DateTitle
01/09/17January 2017 Investor Presentation Download Documentation 
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Akorn, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.